An update from Neurocrine Biosciences and Voyage Therapeutics

  • Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases
  • Neurocrine Biosciences gains development and commercialization rights to gene therapy programs VY-AADC for Parkinson’s disease, VY-FXN01 for Friedreich’s ataxia and two additional programs to be determined
  • Voyager receives $165 million upfront, along with funding for ongoing development of each program, and up to $1.7 billion in potential development, regulatory and commercial milestone payments